During the past decade, Investigational Drug Service conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Investigational Drug Service" are "Arthritis, Rheumatoid" (1 trials) and "Carcinoma, Non-Small-Cell Lung" (1 trials). Many other conditions were trialed in "Investigational Drug Service" in a lesser frequency.

Most popular intervention types in "Investigational Drug Service" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "CP-690,550" (1 trials), "Disease-modifying antirheumatic drug" (1 trials), "Docetaxel" (1 trials), "PF-02341066" (1 trials) and "Pemetrexed" (1 trials). Other intervention names were less common.

The vast majority of trials in "Investigational Drug Service" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Investigational Drug Service". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Investigational Drug Service, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Investigational Drug Service, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".